n.a. (PCYC)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Why Investors Are Writing Off Infinity Pharma

Why Investors Are Writing Off Infinity Pharma

Infinity's B-cell malignancy drug is seen as too far behind competitors but can combination therapy make it more relevant?

Four Biotech 'Surprise' Stocks for 2014

Four Biotech 'Surprise' Stocks for 2014

Biotech investing rarely follows a predictable script, so here's four stocks which may surprise even the most experienced investors in 2014.

Pharmacyclics Larger Than S&P 500 Component Quest Diagnostics

Pharmacyclics Larger Than S&P 500 Component Quest Diagnostics

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Pharmacyclics, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Quest Diagnostics, Inc.

Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts

Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

5 Stocks Spiking on Unusual Volume

5 Stocks Spiking on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Stock Bargains Left on the Table

Skittish buyers are only nibbling and leaving plenty of good cheap stocks for you.

Pharmacyclics' Lymphoma Drug Receives FDA Approval. Cost: $130,000 Per Year!

Pharmacyclics' Lymphoma Drug Receives FDA Approval. Cost: $130,000 Per Year!

Imbruvica will be used to treated mantle cell lymphoma.

'Mad Money' Lightning Round: Pharmacyclics In, Arena Out

'Mad Money' Lightning Round: Pharmacyclics In, Arena Out

Cramer says buy, buy, buy Pharmacyclics and avoid Arena Pharmaceuticals.

Jim Cramer's 6 Stocks in 60 Seconds: PCYC BTU WWAV UAL DE MU (Update 1)

Jim Cramer's 6 Stocks in 60 Seconds: PCYC BTU WWAV UAL DE MU (Update 1)

Cramer thinks Peabody Energy is a China and coal play while he's concerned about Deere.

'Mad Money' Lightning Round: Stay Away From JetBlue

'Mad Money' Lightning Round: Stay Away From JetBlue

Cramer says Wolverine World Wide has been terrific but he's gun-shy on W.P. Carey.

Jim Cramer's 'Mad Money' Recap: A Delicious Rally

Jim Cramer's 'Mad Money' Recap: A Delicious Rally

You want breadth? Only the financial sector hasn't been helped by the market's rally, Cramer says.

First Week Of December 21st Options Trading For Pharmacyclics (PCYC)

First Week Of December 21st Options Trading For Pharmacyclics (PCYC)

Investors in Pharmacyclics, Inc. saw new options become available this week, for the December 21st expiration.

January 2016 Options Now Available For Pharmacyclics (PCYC)

January 2016 Options Now Available For Pharmacyclics (PCYC)

Investors in Pharmacyclics, Inc. saw new options begin trading today, for the January 2016 expiration.

Don't Chase Momentum

The tape is OK for daytrades but risky for position trading, since a deteriorating news flow could unleash a major reversal.

Stocks With Earnings Revised Up

This trend is a good indication that business is going well.

Jim Cramer's Top Stock Picks: DNKN PCYC ARRY GME

Jim Cramer's Top Stock Picks: DNKN PCYC ARRY GME

Cramer says Dunkin Brands has room to grow and he remains a fan of GameStop.

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer will be watching Washington and a number of stocks.

Biotech Stock Mailbag: Astex Pharma, My Essential Twitter Follows

Biotech Stock Mailbag: Astex Pharma, My Essential Twitter Follows

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

The Deal: Royalty Pharma Buys Quest Drug Rights For $485M

The Deal: Royalty Pharma Buys Quest Drug Rights For $485M

The ibrutinib royalty stream came with the acquisition of Celera in 2011.

Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics

Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Pharmacyclics Reaches New 52-Week High (PCYC)

Pharmacyclics Reaches New 52-Week High (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) hit a new 52-week high Wednesday as it is currently trading at $96.44, above its previous 52-week high of $95.85 with 431,164 shares traded as of 9:46 a.m. ET. Average volume has been 814,400 shares over the past 30 days.

Pharmacyclics Stock Falls On Unusually High Volume (PCYC)

Pharmacyclics Stock Falls On Unusually High Volume (PCYC)

Pharmacyclics Incorporated (Nasdaq:PCYC) is trading at unusually high volume Friday with 3.5 million shares changing hands. It is currently at five times its average daily volume and trading down $2.20 (-2.7%).

Winners And Losers in CLL at ASCO '13

Winners And Losers in CLL at ASCO '13

Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged.

ASCO '13 Live Blog: Prepping for Monday Trading

ASCO '13 Live Blog: Prepping for Monday Trading

Charting the drug and biotech stocks which came out ahead at this weekend's ASCO annual meeting, and those that fell behind.

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner

Pharmacyclics Incorporated was a winner within the drugs industry, rising $1.39 (1.5%) to $91.64 on average volume

Making The Call: Pharmacyclics FDA Drug Approval Before Year End

Making The Call: Pharmacyclics FDA Drug Approval Before Year End

The FDA should make a speedy review of ibrutinib a top priority, and with it, sales forecasts will go higher.

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner

Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner

Pharmacyclics Incorporated was a winner within the drugs industry, rising $3.25 (4.0%) to $85.60 on average volume

5 Stocks Raising The Drugs Industry Higher

5 Stocks Raising The Drugs Industry Higher

TheStreet Ratings group highlights 5 stocks pushing the drugs industry higher today.

2013 FDA Drug Approval Calendar

2013 FDA Drug Approval Calendar

An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.

ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up

ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up

New data suggests Roche's GA101 is more potent than the blockbuster Rituxan.